Biosergen H1 FY26 net loss narrows to SEK 10.49 million; EBITDA loss improves to SEK 10.47 million

• Biosergen posted a net loss of SEK 10.49 million for H1 2026, narrowing from SEK 16.19 million a year earlier.
• EBITDA loss narrowed to SEK 10.47 million from SEK 16.18 million, while earnings per share improved to -SEK 4.47 from -SEK 6.89.
• Cash fell to SEK 3.23 million from SEK 33.27 million, leaving equity at SEK 704,000 and solvency at 7%.
• Development of BSG005 was paused to secure financing; Biosergen and Flerie agreed a statutory merger plan.
• Board approved a SEK 40 million rights issue tied to the merger, fully covered by subscription and guarantee undertakings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biosergen AB published the original content used to generate this news brief via Cision (Ref. ID: 202608190300BITN____UKPR__EN_20260818-BIT-9165-0) on August 19, 2026, and is solely responsible for the information contained therein.